Scientists from the research centers of France and Spain, including the University of Paris, have studied the history of people’s disease with a confirmed diagnosis of COVID-19 of 39 hospitals on the subject of receiving antidepressants for mortality from this infection.
In the course of the study, it turned out that the reception of antidepressants with patients with COVID-19 reduces the likelihood of inputs to IVL and death by an average of 20%, writing news.
According to experts, antidepressants increase the motivation of patients: people are more willing to fulfill the recommendations of doctors and have a higher vital tone.
The results of the study showed that antidepressants may be associated with a decrease in the levels of several inflammation mediators that can lead to death from coronavirus. In addition, according to doctors, these drugs are able to have an antiviral effect on coronavirus.
“These results should be interpreted with caution due to observational research design. However, our results confirm the need to conduct controlled randomized clinical trials of antidepressants for the treatment of COVID-19,” scientists say.
At the same time, scientists note that antidepressants have a number of side effects, and take these drugs only strictly by appointment of a doctor.